HCPLive
American Heart Association 2012

American Heart Association 2012 | AHA 2012

According to the AHA, “Scientific Sessions is the leading cardiovascular meeting in the country with over 17,000 professionals attending annually, and over 22,000 total attendees, as reported by the Healthcare Convention and Exhibitor’s Association. Scientific Sessions is the American Heart Association's largest gathering of scientists and healthcare professionals devoted to the science of cardiovascular disease and stroke and the care of patients suffering from these diseases. Programming is designed to improve patient care by communicating the most timely and significant advances in prevention, diagnosis and treatment of cardiovascular disease from many different perspectives.

Conference Coverages

AHA: Increased Cancer Risk for Patients with Heart Failure
AHA: Increased Cancer Risk for Patients with Heart Failure
People with newly diagnosed heart failure are significantly more likely to develop cancer than community controls, according to research presented at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.
Reducing Cardiovascular Events in Patients with Acute Coronary Syndrome
A substudy of the PLATO trial reveals that treatment with ticagrelor reduces cardiovascular death, myocardial infarction, and stroke in some patients with non-ST-elevation acute coronary syndrome.
Serelaxin Shows Promise in Treating Acute Heart Failure
Results from the RELAX-AHF show serelaxin reduces cardiovascular deaths and improves symptoms in patients with heart failure.
Ticagrelor May Reduce Cardiovascular Events in Patients with Extensive Coronary Artery Disease
Results from a substudy of the PLATO trial show that patients with extensive CAD and high rates of recurrent cardiovascular events, death, and bleeding may benefit from treatment with ticagrelor.
AMG145 Lowers LDL Levels in Statin-Intolerant Patients
Subcutaneously administered AMG145, a monoclonal antibody to plasma proprotein convertase subtilisin/kexin type 9, correlates with significant reductions in low-density lipoprotein cholesterol levels in patients who are intolerant to statins due to muscle-related side effects, according to research published online Nov. 5 in the Journal of the American Medical Association to coincide with presentation at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.
Reprogramming Defibrillators Improves Therapy
Reprogramming the firing settings for an implantable cardioverter-defibrillator in patients with heart disease reduces inappropriate firings and reduces death, according to a study published online Nov. 6 in the New England Journal of Medicine to coincide with presentation at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.
Visible Signs of Aging Can Predict Increased Risk of Heart Disease
Study results presented at the American Heart Association 2012 Scientific Sessions show that visible signs of aging such as baldness and yellow fatty deposits around the eye are predictors for heart attack and heart disease risk.

Most Popular

$vacMongoViewPlus$ $vAR$